vs
ASP Isotopes Inc.（ASPI）与SCYNEXIS INC（SCYX）财务数据对比。点击上方公司名可切换其他公司
SCYNEXIS INC的季度营收约是ASP Isotopes Inc.的1.1倍（$18.6M vs $16.7M），SCYNEXIS INC同比增速更快（1808.5% vs 1295.7%）
ASP Isotopes Inc.是一家特种材料企业，专注于高纯度定制同位素的研发与生产，产品广泛应用于核医学、靶向抗癌治疗、清洁能源及工业研究等领域，客户覆盖北美、欧洲及亚太地区。
SCYNEXIS是一家生物科技企业，专注于研发创新抗真菌疗法，用于治疗难治性真菌感染，满足未被覆盖的医疗需求，主要面向医院及专科护理市场，核心产品管线覆盖免疫低下患者等高危人群。
ASPI vs SCYX — 直观对比
营收规模更大
SCYX
是对方的1.1倍
$16.7M
营收增速更快
SCYX
高出512.8%
1295.7%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $16.7M | $18.6M |
| 净利润 | — | $12.3M |
| 毛利率 | 12.5% | — |
| 营业利润率 | — | 56.3% |
| 净利率 | — | 65.7% |
| 营收同比 | 1295.7% | 1808.5% |
| 净利润同比 | -586.8% | 376.5% |
| 每股收益（稀释后） | — | $0.25 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ASPISCYX
| Q4 25 | $16.7M | $18.6M | ||
| Q3 25 | $4.9M | $334.0K | ||
| Q2 25 | — | $1.4M | ||
| Q1 25 | — | $257.0K | ||
| Q4 24 | — | $977.0K | ||
| Q3 24 | — | $660.0K | ||
| Q2 24 | — | $736.0K | ||
| Q1 24 | — | $1.4M |
净利润ASPISCYX
| Q4 25 | — | $12.3M | ||
| Q3 25 | $-12.9M | $-8.6M | ||
| Q2 25 | — | $-6.9M | ||
| Q1 25 | — | $-5.4M | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $-2.8M | ||
| Q2 24 | — | $-14.5M | ||
| Q1 24 | — | $411.0K |
毛利率ASPISCYX
| Q4 25 | 12.5% | — | ||
| Q3 25 | 8.7% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
营业利润率ASPISCYX
| Q4 25 | — | 56.3% | ||
| Q3 25 | -306.1% | -2516.5% | ||
| Q2 25 | — | -701.0% | ||
| Q1 25 | — | -3350.2% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | -1563.6% | ||
| Q2 24 | — | -1255.0% | ||
| Q1 24 | — | -692.5% |
净利率ASPISCYX
| Q4 25 | — | 65.7% | ||
| Q3 25 | -263.7% | -2572.2% | ||
| Q2 25 | — | -504.8% | ||
| Q1 25 | — | -2097.7% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | -425.5% | ||
| Q2 24 | — | -1964.4% | ||
| Q1 24 | — | 29.9% |
每股收益（稀释后）ASPISCYX
| Q4 25 | — | $0.25 | ||
| Q3 25 | $-0.15 | $-0.17 | ||
| Q2 25 | — | $-0.14 | ||
| Q1 25 | — | $-0.11 | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $-0.06 | ||
| Q2 24 | — | $-0.30 | ||
| Q1 24 | — | $0.01 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $333.3M | $40.0M |
| 总债务越低越好 | $14.4M | — |
| 股东权益账面价值 | $204.2M | $49.4M |
| 总资产 | $498.0M | $59.0M |
| 负债/权益比越低杠杆越低 | 0.07× | — |
8季度趋势，按日历期对齐
现金及短期投资ASPISCYX
| Q4 25 | $333.3M | $40.0M | ||
| Q3 25 | $113.9M | $37.9M | ||
| Q2 25 | — | $44.8M | ||
| Q1 25 | — | $40.6M | ||
| Q4 24 | — | $59.3M | ||
| Q3 24 | — | $68.8M | ||
| Q2 24 | — | $73.0M | ||
| Q1 24 | — | $80.2M |
总债务ASPISCYX
| Q4 25 | $14.4M | — | ||
| Q3 25 | $13.9M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益ASPISCYX
| Q4 25 | $204.2M | $49.4M | ||
| Q3 25 | $74.1M | $36.4M | ||
| Q2 25 | — | $44.5M | ||
| Q1 25 | — | $50.5M | ||
| Q4 24 | — | $55.1M | ||
| Q3 24 | — | $58.5M | ||
| Q2 24 | — | $60.4M | ||
| Q1 24 | — | $74.1M |
总资产ASPISCYX
| Q4 25 | $498.0M | $59.0M | ||
| Q3 25 | $225.9M | $51.1M | ||
| Q2 25 | — | $60.7M | ||
| Q1 25 | — | $67.9M | ||
| Q4 24 | — | $90.6M | ||
| Q3 24 | — | $99.0M | ||
| Q2 24 | — | $107.8M | ||
| Q1 24 | — | $118.3M |
负债/权益比ASPISCYX
| Q4 25 | 0.07× | — | ||
| Q3 25 | 0.19× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-37.8M | $18.4M |
| 自由现金流经营现金流 - 资本支出 | $-47.4M | — |
| 自由现金流率自由现金流/营收 | -284.7% | — |
| 资本支出强度资本支出/营收 | 57.9% | — |
| 现金转化率经营现金流/净利润 | — | 1.50× |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流ASPISCYX
| Q4 25 | $-37.8M | $18.4M | ||
| Q3 25 | $-8.9M | $-8.7M | ||
| Q2 25 | — | $-7.5M | ||
| Q1 25 | — | $-7.5M | ||
| Q4 24 | — | $-24.0M | ||
| Q3 24 | — | $765.0K | ||
| Q2 24 | — | $-10.9M | ||
| Q1 24 | — | $-4.0M |
自由现金流ASPISCYX
| Q4 25 | $-47.4M | — | ||
| Q3 25 | $-12.0M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
自由现金流率ASPISCYX
| Q4 25 | -284.7% | — | ||
| Q3 25 | -245.5% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
资本支出强度ASPISCYX
| Q4 25 | 57.9% | — | ||
| Q3 25 | 64.4% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金转化率ASPISCYX
| Q4 25 | — | 1.50× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | -9.75× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ASPI
暂无分部数据
SCYX
| Glaxosmithkline Intellectual Property | $17.2M | 92% |
| Products | $1.4M | 8% |
